Stocks & ETFs

CRISPR Soars More Than 80% On Expected FDA Approval

The legendary gene editing technology behaves like a molecular adaptor that can be used to modify a DNA sequence.

The Insider

By

bantinginc

CRISPR Soars More Than 80% On Expected FDA Approval

The CRISPR Advantage


CRISPR Therapeutics (CRISPR) shares have soared 84% in the last month on the back of an expected FDA approval for the first treatment based on CRISPR technology.

The company specializes in utilizing a gene editing platform (CRISPR) to develop medicines for the treatment of various rare and common diseases. The legendary gene editing technology behaves like a molecular adaptor that can be used to modify a DNA sequence.

The Approvals


Regulators in the U.K. have already approved the first CRISPR based treatment for sickle cell disease and beta-thalassemia patients. The FDA is currently considering approving the same CRISPR based treatment for sickle cell disease in the United States at some point in December 2023. 

The Future


CRISPR treatments may likely save many lives and provide the basis for resistance to rare and common diseases into the future. And of course, on that same point, CRISPR approved gene editing treatments will provide new revenue sources for the company as a whole. CRISPR has always been a company to watch but now they may just be the company to buy as the FDA considers the future of medicine.


Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top